ANTHEM935.35

Anthem Biosciences Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersSYNGENEDIVISLABGLAXOAJANTPHARMIPCALABABBOTINDIAMEDANTAGLENMARKMcap ₹52,540 Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations540.2550.0423.2610.9418.2
Other Income22.848.233.551.224.9
Total Income563.0598.3456.7662.2443.1
Expenses
+ Cost of Materials Consumed162.2201.3184.9165.2148.6
+ Changes in Inventories68.722.1-42.350.3-2.4
+ Employee Benefit Expense72.067.770.572.578.8
+ Finance Costs1.63.00.41.90.9
+ Depreciation & Amortisation26.433.534.539.630.0
+ Other Expenses45.841.052.955.842.6
Total Expenses376.8368.7300.8385.2298.5
EBITDA191.5217.9157.2267.2150.6
EBIT165.0184.4122.7227.6120.6
Profit
PBT before Exceptional Items186.2229.6155.8276.9144.6
+ Exceptional Items0.00.0-25.41.00.0
Pretax Income186.2229.6130.5277.9144.6
+ Current Tax50.163.837.889.734.7
+ Deferred Tax0.4-7.6-0.1-1.5-10.1
Tax Expense50.556.237.788.224.6
Net Income135.8173.492.8189.8119.9
+ Net Income — Continuing Ops135.8173.492.8189.8119.9
+ Other Comprehensive Income1.5-1.5-0.8-0.80.9
Total Comprehensive Income137.3171.992.0189.0120.9
Per Share
Basic EPS2.433.091.650.002.13
Diluted EPS2.423.061.640.002.11
Other Comprehensive Income — detail
+ Other Comprehensive Income1.5-1.5-0.8-0.80.9
+ Items NOT to be Reclassified to P&L1.5-1.5-1.1-0.80.9
+ Tax on Items NOT to be Reclassified0.00.0-0.30.00.2
+ Items to be Reclassified to P&L0.3
+ Tax on Items to be Reclassified0.00.1
Per Share — as-filed variants
Basic EPS — Continuing Operations2.433.091.650.002.13
Diluted EPS — Continuing Operations2.423.061.640.002.11
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit309.3326.7280.6395.5272.0
Gross Margin %57.2659.3966.3064.7365.04
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)186.2229.6155.8276.9144.6
− Exceptional Items (reconciliation)0.00.0-25.41.00.0
Net Income Adj (tax-effected)135.8173.4110.9189.1119.9
EPS Adj2.433.091.970.002.13
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value2.002.002.002.002.00
Filed Debt Equity0.000.000.000.01
Filed Dscr0.370.270.340.29
Filed Iscr1.170.771.101.64
Paid Up Equity Capital112.3112.3112.3112.3112.7
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.